Your browser doesn't support javascript.
loading
Metabolomics at the tumor microenvironment interface: Decoding cellular conversations.
Berrell, Naomi; Sadeghirad, Habib; Blick, Tony; Bidgood, Charles; Leggatt, Graham R; O'Byrne, Ken; Kulasinghe, Arutha.
Afiliación
  • Berrell N; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Sadeghirad H; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Blick T; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Bidgood C; APCRC-Q, Queensland University of Technology, Brisbane, Queensland, Australia.
  • Leggatt GR; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • O'Byrne K; Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
  • Kulasinghe A; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Med Res Rev ; 44(3): 1121-1146, 2024 05.
Article en En | MEDLINE | ID: mdl-38146814
ABSTRACT
Cancer heterogeneity remains a significant challenge for effective cancer treatments. Altered energetics is one of the hallmarks of cancer and influences tumor growth and drug resistance. Studies have shown that heterogeneity exists within the metabolic profile of tumors, and personalized-combination therapy with relevant metabolic interventions could improve patient response. Metabolomic studies are identifying novel biomarkers and therapeutic targets that have improved treatment response. The spatial location of elements in the tumor microenvironment are becoming increasingly important for understanding disease progression. The evolution of spatial metabolomics analysis now allows scientists to deeply understand how metabolite distribution contributes to cancer biology. Recently, these techniques have spatially resolved metabolite distribution to a subcellular level. It has been proposed that metabolite mapping could improve patient outcomes by improving precision medicine, enabling earlier diagnosis and intraoperatively identifying tumor margins. This review will discuss how altered metabolic pathways contribute to cancer progression and drug resistance and will explore the current capabilities of spatial metabolomics technologies and how these could be integrated into clinical practice to improve patient outcomes.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Microambiente Tumoral / Neoplasias Límite: Humans Idioma: En Revista: Med Res Rev Año: 2024 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Microambiente Tumoral / Neoplasias Límite: Humans Idioma: En Revista: Med Res Rev Año: 2024 Tipo del documento: Article País de afiliación: Australia